Rescue PCI after failed fibrinolysis linked to worse outcomes in STEMI compared to scheduled angiography
Rescue PCI after failed clot-busting drugs caused worse heart outcomes than planned angiography
This pre-specified analysis of the STREAM-2 RCT compared rescue PCI after failed fibrinolysis with scheduled angiography in 583 patients wit…
Patients needing emergency heart catheterization after clot-busting drugs fared worse than those who received planned procedures, with highe…
Tenecteplase shows worse functional outcomes in older patients with minor ischemic stroke compared to standard care.
The Clot-Busting Drug That Backfires in Patients Over 80
This post hoc analysis of a randomized controlled trial evaluated tenecteplase versus nonthrombolytic standard of care in 884 patients with …
In patients over 80 with minor stroke, a clot-busting drug improved short-term recovery but worsened outcomes at 90 days compared to standar…
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke.
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
This randomized, open-label, blinded end-point trial evaluated intravenous tenecteplase versus standard medical treatment in 570 patients wi…
Tenecteplase helps late-arriving stroke patients recover better but raises bleeding risk, giving doctors a new tool for those beyond the usu…
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again.
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.